Sangamo Therapeutics, Inc. has filed a voluntary petition for relief under Chapter 11 of the United States Bankruptcy Code. The filing was made on June 23, 2026, with the United States Bankruptcy Court for the District of Delaware. The case is styled as In re Sangamo Therapeutics, Inc. and has been assigned case number 26-10989.
The company is operating as a debtor-in-possession under sections 1107(a) and 1108 of the Bankruptcy Code. In connection with this filing, the company has submitted monthly operating reports for the periods ending July 31, 2026, August 31, 2026, and September 30, 2026. These reports are attached as exhibits to the current filing.
The company’s common stock was suspended from trading on the Nasdaq Capital Market on May 5, 2026. Following a determination by Nasdaq to delist the shares, the company’s stock was delisted effective October 17, 2026. Currently, the stock trades on the OTC Expert Market on an unsolicited quotes only basis.
According to the Amended Monthly Operating Report for the period ended July 31, 2026, the company reported total assets of approximately $155.1 million and total liabilities of approximately $97.1 million. The report indicates an ending cash balance of $16.9 million for that period. The company reported a net loss of $11.2 million for the month of July.
The company has cautioned investors that trading in its common stock during the bankruptcy process is highly speculative and poses substantial risks. The company also noted that trading prices for the stock may bear little or no relationship to the actual recovery investors might receive in the bankruptcy case.
